{
  "stage": "S3",
  "passed": false,
  "convergence_score": 0.939,
  "convergence_threshold": 0.85,
  "convergence_pass": true,
  "jaccard": 0.4667,
  "jaccard_threshold": 0.85,
  "jaccard_pass": false,
  "type_01_ratio": 0.7273,
  "type_01_threshold": 0.75,
  "type_pass": false,
  "cosine": 0.939,
  "jsd": 0.1719,
  "kappa": 0.9309,
  "type_distribution": {
    "0": 0.5909090909090909,
    "1": 0.13636363636363635,
    "2": 0.18181818181818182,
    "3": 0.09090909090909091
  },
  "divergence_map": {
    "total_unique_claims": 22,
    "most_divergent": [
      {
        "statement": "1**: Drp1-mediated fission constriction is pharmacologically irrelevant for VDAC1-targeting drugs with \u00b5M Kd.",
        "models_supporting": [
          "claude"
        ],
        "types_assigned": [
          2
        ],
        "confidences": [
          0.8
        ],
        "type_variance": 0,
        "n_supporters": 1
      },
      {
        "statement": "2**: VDAC1 surface density is approximately conserved (~3,000-5,000 copies/\u00b5m\u00b2) regardless of fission/fusion state.",
        "models_supporting": [
          "claude"
        ],
        "types_assigned": [
          2
        ],
        "confidences": [
          0.65
        ],
        "type_variance": 0,
        "n_supporters": 1
      },
      {
        "statement": "3**: Mfn2-dependent ER-mito contact sites enrich OMM cholesterol by 5-15 mol%, shifting VDAC1 toward closed state and reducing CBD binding affinity by ~2-5 fold.",
        "models_supporting": [
          "claude"
        ],
        "types_assigned": [
          2
        ],
        "confidences": [
          0.55
        ],
        "type_variance": 0,
        "n_supporters": 1
      },
      {
        "statement": "4**: VDAC1 hexagonal supralattice requires flat membrane domains \u226580-120 nm; fragmented mitochondria (radius ~150 nm) retain reduced flat patches, shifting equilibrium toward monomers/dimers with distinct pharmacological profiles.",
        "models_supporting": [
          "claude"
        ],
        "types_assigned": [
          3
        ],
        "confidences": [
          0.35
        ],
        "type_variance": 0,
        "n_supporters": 1
      },
      {
        "statement": "5**: Mdivi-1 (Drp1 inhibitor) indirectly reduces VDAC1 drug accessibility by promoting fusion, increasing ER-mito contacts, enriching OMM cholesterol, and stabilizing closed VDAC1.",
        "models_supporting": [
          "claude"
        ],
        "types_assigned": [
          3
        ],
        "confidences": [
          0.4
        ],
        "type_variance": 0,
        "n_supporters": 1
      },
      {
        "statement": "1:** Drp1-mediated fission induces transient, high-curvature OMM constriction that distorts VDAC1\u2019s \u03b2-barrel, reducing pore conductance and altering drug-binding pockets, but does not force stable oligomerization.",
        "models_supporting": [
          "mistral"
        ],
        "types_assigned": [
          1
        ],
        "confidences": [
          0.75
        ],
        "type_variance": 0,
        "n_supporters": 1
      },
      {
        "statement": "2:** VDAC1 density per unit OMM area is conserved (~3,000 copies/\u00b5m\u00b2) between fragmented and fused mitochondria, but fragmentation reduces the size of VDAC1\u2019s hexagonal lattice domains, shifting equilibrium toward monomers/dimers.",
        "models_supporting": [
          "mistral"
        ],
        "types_assigned": [
          2
        ],
        "confidences": [
          0.6
        ],
        "type_variance": 0,
        "n_supporters": 1
      },
      {
        "statement": "3:** Mfn2-mediated cholesterol transfer at ER-mitochondria contacts stabilizes VDAC1 in a closed, low-conductance state, reducing accessibility of pore-targeting drugs (e.g., CBD) by 2\u20134-fold.",
        "models_supporting": [
          "mistral"
        ],
        "types_assigned": [
          1
        ],
        "confidences": [
          0.65
        ],
        "type_variance": 0,
        "n_supporters": 1
      },
      {
        "statement": "4:** Dynamics-targeting drugs (e.g., mdivi-1) indirectly reduce VDAC1-targeting drug efficacy by promoting fusion, which enriches OMM cholesterol (via Mfn2) and stabilizes VDAC1\u2019s closed state.",
        "models_supporting": [
          "mistral"
        ],
        "types_assigned": [
          3
        ],
        "confidences": [
          0.5
        ],
        "type_variance": 0,
        "n_supporters": 1
      },
      {
        "statement": "5:** The transient VDAC1 distortion during fission is pharmacologically irrelevant for drugs with slow binding kinetics (e.g., CBD, Kd = 11 \u00b5M), as the fission neck\u2019s lifetime (~1\u201310 ms) is orders of magnitude shorter than the drug\u2019s residence time (~seconds).",
        "models_supporting": [
          "mistral"
        ],
        "types_assigned": [
          1
        ],
        "confidences": [
          0.8
        ],
        "type_variance": 0,
        "n_supporters": 1
      }
    ],
    "models_present": [
      "claude",
      "mistral",
      "grok",
      "gemini",
      "deepseek"
    ]
  },
  "recommendation": "S3 gate FAILED. The system did not converge to stable consensus. This indicates genuine scientific disagreement worth investigating. Review the divergence map below."
}